Gsk (GSK) Non-Current Debt (2009 - 2026)
Gsk (GSK) posted quarterly Non-Current Debt of -$18.7 billion for Q2 2026, up 8.35% year-over-year from -$17.3 billion in Q2 2025, and up 0.94% quarter-over-quarter from -$18.9 billion in Q1 2026.
Gsk (GSK) Non-Current Debt (2009 - 2026) Analysis & Trends
Gsk's Non-Current Debt history runs 18 years deep, the most recent figure standing at -$18.7 billion for Q2 2026.
- In Q2 2026, Non-Current Debt rose 8.35% year-over-year to -$18.7 billion; the TTM figure through Jun 2026 stood at -$18.7 billion (up 8.35% YoY), while the FY2025 annual figure was -$19.4 billion, down 203.91% from the prior year.
- Non-Current Debt for Q2 2026 stood at -$18.7 billion, up from -$18.9 billion in the prior quarter.
- The five-year high for Non-Current Debt was $18.9 billion in Q4 2023, with the low at -$23.7 billion in Q2 2022.
- The 5-year median for Non-Current Debt is -$19.3 billion (2023), against an average of -$13.7 billion.
- The sharpest annual moves came in 2023 and 2025: Non-Current Debt jumped 178.32% in 2023, then sank 204.4% in 2025.
- Gsk's Non-Current Debt stood at $6.8 billion in 2022, then surged by 178.32% to $18.9 billion in 2023, then retreated by 0.67% to $18.7 billion in 2024, then tumbled by 204.4% to -$19.6 billion in 2025, then advanced by 4.35% to -$18.7 billion in 2026.
- Business Quant data shows GSK's Non-Current Debt at -$18.7 billion in Q2 2026, -$18.9 billion in Q1 2026, and -$19.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.66 Bn | 632.90 Bn | 17.26 Bn | 37.34 Bn |
| 2 | AbbVie | 469.84 Bn | 463.27 Bn | 12.70 Bn | 62.48 Bn |
| 3 | Merck | 378.23 Bn | 371.09 Bn | 12.21 Bn | 51.08 Bn |
| 4 | Novartis Ag | 303.01 Bn | 295.32 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 258.57 Bn | 253.67 Bn | 12.86 Bn | 23.68 Bn |
| 6 | Amgen | 237.36 Bn | 223.37 Bn | 7.24 Bn | 57.30 Bn |
| 7 | Gilead Sciences | 183.27 Bn | 180.09 Bn | 6.22 Bn | 26.25 Bn |
| 8 | Pfizer | 160.74 Bn | 149.04 Bn | 10.94 Bn | 60.50 Bn |
| 9 | Gsk | 105.88 Bn | 101.72 Bn | 8.24 Bn | -18.71 Bn |
| 10 | Sanofi | 55.28 Bn | 47.90 Bn | 10.79 Bn | 17.02 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.71 Bn |
| Mar 31, 2026 | -18.89 Bn |
| Dec 31, 2025 | -19.56 Bn |
| Sep 30, 2025 | -20.10 Bn |
| Jun 30, 2025 | -20.42 Bn |
| Mar 31, 2025 | -20.75 Bn |
| Dec 31, 2024 | 18.74 Bn |
| Sep 30, 2024 | -17.21 Bn |
| Jun 30, 2024 | -17.14 Bn |
| Mar 31, 2024 | -19.23 Bn |
| Dec 31, 2023 | 18.87 Bn |
| Sep 30, 2023 | -20.26 Bn |
| Jun 30, 2023 | -19.46 Bn |
| Mar 31, 2023 | -20.23 Bn |
| Dec 31, 2022 | 6.78 Bn |
| Sep 30, 2022 | -22.77 Bn |
| Jun 30, 2022 | -23.65 Bn |
| Mar 31, 2022 | -12.56 Bn |
| Dec 31, 2021 | 6.90 Bn |
| Sep 30, 2021 | -28.59 Bn |